Latest Ratios: P/E Ratio 2.7x · EV/EBITDA 2.2x · ROE 5.9%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.7B | $3.4B | $3.4B | $3.2B | — | — | — | — | — | — | — |
| Enterprise Value | $4.5B | $4.1B | $3.3B | $3.4B | — | — | — | — | — | — | — |
| P/E Ratio → | 2.70 | 13.54 | 5.37 | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.67 | 0.59 | 0.63 | 0.75 | — | — | — | — | — | — | — |
| P/B Ratio | 0.56 | 0.68 | 0.84 | 1.03 | — | — | — | — | — | — | — |
| P/FCF | 0.78 | 0.72 | 0.57 | 0.55 | — | — | — | — | — | — | — |
| P/OCF | 0.79 | 0.72 | 0.57 | 0.55 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.72 | 0.62 | 0.80 | — | — | — | — | — | — | — |
| EV / EBITDA | 2.19 | 4.16 | 2.49 | 9.03 | — | — | — | — | — | — | — |
| EV / EBIT | 13.82 | 8.44 | 3.68 | 54.88 | — | — | — | — | — | — | — |
| EV / FCF | — | 0.88 | 0.56 | 0.59 | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.8% | 30.8% | 30.1% | 16.8% | 49.7% | 42.9% | 100.0% | 36.7% | 100.0% | 100.0% | 100.0% |
| Operating Margin | 5.6% | 5.6% | 14.4% | -0.8% | 35.4% | 45.8% | 93.1% | 23.2% | 8.2% | 12.7% | -31.6% |
| Net Profit Margin | 4.6% | 4.6% | 11.8% | -1.4% | 28.4% | 36.6% | -12.4% | 22.7% | -2.3% | -56.4% | -31.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.9% | 5.9% | 17.8% | -2.1% | 18.4% | 29.0% | -5.2% | 22.4% | -1.1% | -112.1% | -6.7% |
| ROA | 0.3% | 0.3% | 0.8% | -0.1% | 1.2% | 2.8% | -0.5% | 1.2% | -0.1% | -7.3% | -0.0% |
| ROIC | 5.0% | 5.0% | 16.0% | -0.9% | 18.3% | 30.1% | 32.6% | 19.6% | 4.2% | 31.8% | — |
| ROCE | 0.4% | 0.4% | 1.2% | -0.1% | 1.5% | 3.5% | 3.5% | 1.2% | 0.2% | 1.6% | -0.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.45 | 0.45 | 0.54 | 0.57 | 0.47 | 0.22 | 0.15 | 0.20 | 0.59 | 0.21 | — |
| Debt / EBITDA | 2.26 | 2.26 | 1.62 | 4.68 | 1.01 | 0.54 | 0.42 | 0.99 | 5.36 | 1.27 | — |
| Net Debt / Equity | — | 0.15 | -0.02 | 0.07 | 0.07 | -0.12 | -0.07 | -0.15 | -0.03 | -0.40 | -0.20 |
| Net Debt / EBITDA | 0.76 | 0.76 | -0.06 | 0.54 | 0.15 | -0.30 | -0.20 | -0.78 | -0.30 | -2.48 | — |
| Debt / FCF | — | 0.16 | -0.01 | 0.03 | 0.05 | -0.29 | -8.17 | -0.67 | -0.03 | -0.80 | — |
| Interest Coverage | 2.97 | 2.97 | 6.89 | 0.64 | 28.34 | 54.52 | — | 14.16 | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | — | — | 4.12 | — | — | 161.50 | — | 7.51 | 7.05 | 28.26 | 14.52 |
| Quick Ratio | — | — | 4.12 | — | — | 161.50 | — | 7.51 | 7.05 | 28.26 | 14.52 |
| Cash Ratio | — | — | 4.12 | — | — | 144.85 | — | 7.51 | 7.05 | 28.26 | 14.52 |
| Asset Turnover | — | 0.06 | 0.06 | 0.06 | 0.04 | 0.07 | 0.04 | 0.05 | 0.02 | 0.07 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 5.0% | 4.1% | 3.5% | 3.2% | — | — | — | — | — | — | — |
| Payout Ratio | 51.7% | 51.7% | 18.9% | — | — | — | — | 2.2% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 37.1% | 7.4% | 18.6% | — | — | — | — | — | — | — | — |
| FCF Yield | 100.0% | 138.9% | 174.1% | 181.4% | — | — | — | — | — | — | — |
| Buyback Yield | 0.3% | 0.3% | 0.3% | 0.6% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 5.3% | 4.4% | 3.9% | 3.7% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $132M | $131M | $124M | $115M | $105M | $150M | $213M | $216M | $214M | $19M |
Includes 30+ ratios · 10 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FGN stock.
F&G Annuities & Life, Inc.'s current P/E ratio is 2.7x. The historical average is 9.5x.
F&G Annuities & Life, Inc.'s current EV/EBITDA is 2.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 5.2x.
F&G Annuities & Life, Inc.'s return on equity (ROE) is 5.9%. The historical average is -3.4%.
Based on historical data, F&G Annuities & Life, Inc. is trading at a P/E of 2.7x. Compare with industry peers and growth rates for a complete picture.
F&G Annuities & Life, Inc.'s current dividend yield is 4.99% with a payout ratio of 51.7%.
F&G Annuities & Life, Inc. has 30.8% gross margin and 5.6% operating margin.
F&G Annuities & Life, Inc.'s Debt/EBITDA ratio is 2.3x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
Thin spread-driven margin cushion
Metrics are mathematically derived from official filings.
Deep Discount Reflects Earnings Skepticism
Based on reported figures, FGN trades at 0.58 times book value and 2.81 times trailing earnings, a sharp discount to Globe Life's 2.18 times book, suggesting the market doubts the durability of reported earnings relative to book value.
A sub-1.0 P/B for an insurer with a 5.9% ROE implies the market is pricing in returns below the cost of equity, which is consistent with the thin 4.6% net margin and volatile quarterly results. The low trailing P/E is likely inflated by a single large quarter in 2026Q3 rather than representing steady earnings power, so investors should monitor whether the discount narrows as the earnings base normalizes. The valuation gap versus higher-ROE peers such as LNC and GL appears to reflect quality-of-earnings concerns more than franchise weakness.
Combined Ratio Volatility Undermines Consistency
As reported in the ratio data, FGN's combined ratio ranged from 72.0% to 106.6% across ten quarters, with the loss ratio spiking to 80.9% in 2026Q2, indicating benefit experience dominates underwriting outcomes.
Four of the ten quarters show a combined ratio above 100%, which suggests the underwriting result is highly sensitive to claim timing and reserve assumptions rather than to a stable pricing spread. The compression in expense ratio from 41.7% in 2025Q1 to 8.9% in 2024Q4 indicates that acquisition cost accounting is also a meaningful source of quarterly noise. Investors should treat any single-quarter combined ratio as unrepresentative and weight the multi-quarter trend more heavily.
Spread Income Carries Thin ROE
Based on FGN's reported figures, ROE of 5.9% against an asset base of roughly $103.8B yields a return on assets near 0.4%, indicating that the leverage-driven model produces modest returns on shareholder capital.
The gap between a 5.9% ROE and the large asset base highlights how heavily returns depend on the net interest spread earned on policyholder-funded liabilities. Because the trailing ROA is well below typical insurer benchmarks, limited cushion exists against spread compression or adverse investment performance. The 2026Q3 ROE of 16.2% appears to be an outlier driven by a single large quarter, so the sustainable return profile likely sits closer to the lower multi-quarter average.
Policyholder Liabilities Dwarf Equity Base
As reported in the balance sheet, FGN's equity of roughly $4.4B supports about $99.4B of liabilities in 2026Q3, and the reported debt-to-equity of 0.45% appears to understate effective leverage.
Policyholder obligations, not financial debt, are the dominant claim on the balance sheet, so the reported low D/E ratio does not capture the true leverage embedded in the annuity book. The asset-to-equity multiple, roughly 23 times, is the more meaningful measure of how thinly capital is spread against invested assets. Rating agency and regulatory capital adequacy, which the supplied data does not report, would be the appropriate tests of whether this leverage is sustainable.
P/B Misreads Insurer Economics
Based on reported figures, the 0.58 times price-to-book multiple is the ratio most likely to be misapplied to FGN, since book value is largely invested assets backing policy reserves rather than a clean measure of distributable equity.
A low P/B can be read as cheap, but for an annuity writer book value embeds reserve assumptions and unrealized investment marks that may not represent economic value. Adjusted operating earnings, which strip out derivative and market volatility, and embedded value measures would give a more reliable anchor than headline P/B or trailing P/E. Investors should treat the apparent discount as a hypothesis to test against these adjusted measures rather than as evidence of mispricing.